NCT01514201 - Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2012

Primary Completion Date

March 28, 2018

Study Completion Date

March 28, 2018

Conditions

Anaplastic AstrocytomaBrain Stem GliomaChildhood Mixed GliomaFibrillary AstrocytomaGiant Cell GlioblastomaGlioblastomaGliosarcomaUntreated Childhood Anaplastic AstrocytomaUntreated Childhood Brain Stem GliomaUntreated Childhood Fibrillary AstrocytomaUntreated Childhood Giant Cell GlioblastomaUntreated Childhood GlioblastomaUntreated Childhood Gliosarcoma

Interventions

RADIATION

3-Dimensional Conformal Radiation Therapy

Undergo 3D-CRT

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Temozolomide

Given PO

DRUG

Veliparib

Given PO

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

27710

Duke University Medical Center, Durham

38105

Pediatric Brain Tumor Consortium, Memphis

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Lurie Children's Hospital-Chicago, Chicago

77030

Texas Children's Hospital, Houston

90027

Children's Hospital Los Angeles, Los Angeles

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH